Literature DB >> 21595499

Lentiviral-mediated gene transfer to the sheep brain: implications for gene therapy in Batten disease.

Kathryn S Linterman1, David N Palmer, Graham W Kay, Lucy A Barry, Nadia L Mitchell, Robin G McFarlane, Michael A Black, Mark S Sands, Stephanie M Hughes.   

Abstract

The neuronal ceroid lipofuscinoses (NCLs; Batten disease) are inherited neurodegenerative lysosomal storage diseases with common clinical features of blindness and seizures culminating in premature death. Gene-therapy strategies for these diseases depend on whether the missing activity is a secreted lysosomal protein taken up by neighboring cells, or an intramembrane protein that requires careful targeting. Therapies are best developed in animal models with large complex human-like brains. Lentiviral-mediated gene delivery to neural cell cultures from normal sheep and sheep affected with an NCL resulted in green fluorescent protein (GFP) expression in neurons and neuroblasts, more efficiently than in astrocytes. Similar transgene expression was obtained from two constitutive promoters, the viral MND promoter and the human EF1α promoter. In vivo studies showed stable and persistent GFP expression throughout the cell bodies, axons, and dendrites from intracortical injections and indicated ependymal and subependymal transduction. The sheep showed no ill effects from the injections. These data support continuing gene-therapy trials in the sheep models of Batten disease.

Entities:  

Mesh:

Substances:

Year:  2011        PMID: 21595499      PMCID: PMC3159522          DOI: 10.1089/hum.2011.026

Source DB:  PubMed          Journal:  Hum Gene Ther        ISSN: 1043-0342            Impact factor:   5.695


  51 in total

1.  Lentiviral gene delivery to CNS by spinal intrathecal administration to neonatal mice.

Authors:  Elena Fedorova; Lorenzo Battini; Ainu Prakash-Cheng; Daniele Marras; G Luca Gusella
Journal:  J Gene Med       Date:  2006-04       Impact factor: 4.565

2.  Partial neuroprotection with low-dose infusion of the alpha2-adrenergic receptor agonist clonidine after severe hypoxia in preterm fetal sheep.

Authors:  Justin M Dean; Sherly George; Andrew S Naylor; Carina Mallard; Alistair J Gunn; Laura Bennet
Journal:  Neuropharmacology       Date:  2008-05-18       Impact factor: 5.250

3.  Comparison of five retrovirus vectors containing the human IL-2 receptor gamma chain gene for their ability to restore T and B lymphocytes in the X-linked severe combined immunodeficiency mouse model.

Authors:  G J Avilés Mendoza; N E Seidel; M Otsu; S M Anderson; K Simon-Stoos; A Herrera; S Hoogstraten-Miller; H L Malech; F Candotti; J M Puck; D M Bodine
Journal:  Mol Ther       Date:  2001-04       Impact factor: 11.454

4.  A missense mutation (c.184C>T) in ovine CLN6 causes neuronal ceroid lipofuscinosis in Merino sheep whereas affected South Hampshire sheep have reduced levels of CLN6 mRNA.

Authors:  Imke Tammen; Peter J Houweling; Tony Frugier; Nadia L Mitchell; Graham W Kay; Julie A L Cavanagh; Roger W Cook; Herman W Raadsma; David N Palmer
Journal:  Biochim Biophys Acta       Date:  2006-09-12

5.  Tay-Sachs disease in Jacob sheep.

Authors:  Paola A Torres; Bai Jin Zeng; Brian F Porter; Joseph Alroy; Fred Horak; Joan Horak; Edwin H Kolodny
Journal:  Mol Genet Metab       Date:  2010-08-14       Impact factor: 4.797

6.  Mutations in a novel CLN6-encoded transmembrane protein cause variant neuronal ceroid lipofuscinosis in man and mouse.

Authors:  Hanlin Gao; Rose-Mary N Boustany; Janice A Espinola; Susan L Cotman; Lakshmi Srinidhi; Kristen Auger Antonellis; Tammy Gillis; Xuebin Qin; Shumei Liu; Leah R Donahue; Roderick T Bronson; Jerry R Faust; Derek Stout; Jonathan L Haines; Terry J Lerner; Marcy E MacDonald
Journal:  Am J Hum Genet       Date:  2001-12-21       Impact factor: 11.025

7.  Enhanced survival of the LINCL mouse following CLN2 gene transfer using the rh.10 rhesus macaque-derived adeno-associated virus vector.

Authors:  Dolan Sondhi; Neil R Hackett; Daniel A Peterson; Jamie Stratton; Michael Baad; Kelly M Travis; James M Wilson; Ronald G Crystal
Journal:  Mol Ther       Date:  2006-12-19       Impact factor: 11.454

8.  Neuronal ceroid-lipofuscinosis in Borderdale sheep.

Authors:  R D Jolly; D G Arthur; G W Kay; D N Palmer
Journal:  N Z Vet J       Date:  2002-10       Impact factor: 1.628

9.  The mouse ortholog of the neuronal ceroid lipofuscinosis CLN5 gene encodes a soluble lysosomal glycoprotein expressed in the developing brain.

Authors:  Ville Holmberg; Anu Jalanko; Juha Isosomppi; Anna-Liisa Fabritius; Leena Peltonen; Outi Kopra
Journal:  Neurobiol Dis       Date:  2004-06       Impact factor: 5.996

10.  Lysine 43 is trimethylated in subunit C from bovine mitochondrial ATP synthase and in storage bodies associated with batten disease.

Authors:  Ruming Chen; Ian M Fearnley; David N Palmer; John E Walker
Journal:  J Biol Chem       Date:  2004-03-09       Impact factor: 5.157

View more
  11 in total

Review 1.  Viral vector-based tools advance knowledge of basal ganglia anatomy and physiology.

Authors:  Rachel J Sizemore; Sonja Seeger-Armbruster; Stephanie M Hughes; Louise C Parr-Brownlie
Journal:  J Neurophysiol       Date:  2016-02-17       Impact factor: 2.714

Review 2.  Gene therapy approaches in the non-human primate model of Parkinson's disease.

Authors:  D Pignataro; D Sucunza; A J Rico; I G Dopeso-Reyes; E Roda; A I Rodríguez-Perez; J L Labandeira-Garcia; V Broccoli; S Kato; K Kobayashi; José L Lanciego
Journal:  J Neural Transm (Vienna)       Date:  2017-01-27       Impact factor: 3.575

3.  Chimeric rabies SADB19-VSVg-pseudotyped lentiviral vectors mediate long-range retrograde transduction from the mouse spinal cord.

Authors:  L Schoderboeck; S Riad; A M Bokor; H E Wicky; M Strauss; M Bostina; M J Oswald; R M Empson; S M Hughes
Journal:  Gene Ther       Date:  2015-01-29       Impact factor: 5.250

4.  Longitudinal In Vivo Monitoring of the CNS Demonstrates the Efficacy of Gene Therapy in a Sheep Model of CLN5 Batten Disease.

Authors:  Nadia L Mitchell; Katharina N Russell; Martin P Wellby; Hollie E Wicky; Lucia Schoderboeck; Graham K Barrell; Tracy R Melzer; Steven J Gray; Stephanie M Hughes; David N Palmer
Journal:  Mol Ther       Date:  2018-07-17       Impact factor: 11.454

Review 5.  A lysosomal enigma CLN5 and its significance in understanding neuronal ceroid lipofuscinosis.

Authors:  I Basak; H E Wicky; K O McDonald; J B Xu; J E Palmer; H L Best; S Lefrancois; S Y Lee; L Schoderboeck; S M Hughes
Journal:  Cell Mol Life Sci       Date:  2021-04-01       Impact factor: 9.261

Review 6.  Lentiviral vectors as tools to understand central nervous system biology in mammalian model organisms.

Authors:  Louise C Parr-Brownlie; Clémentine Bosch-Bouju; Lucia Schoderboeck; Rachel J Sizemore; Wickliffe C Abraham; Stephanie M Hughes
Journal:  Front Mol Neurosci       Date:  2015-05-18       Impact factor: 5.639

7.  Rapid and Progressive Regional Brain Atrophy in CLN6 Batten Disease Affected Sheep Measured with Longitudinal Magnetic Resonance Imaging.

Authors:  Stephen J Sawiak; Sunthara Rajan Perumal; Skye R Rudiger; Loren Matthews; Nadia L Mitchell; Clive J McLaughlan; C Simon Bawden; David N Palmer; Timothy Kuchel; A Jennifer Morton
Journal:  PLoS One       Date:  2015-07-10       Impact factor: 3.240

8.  RNA-Sequencing Analysis Reveals a Regulatory Role for Transcription Factor Fezf2 in the Mature Motor Cortex.

Authors:  Alison J Clare; Hollie E Wicky; Ruth M Empson; Stephanie M Hughes
Journal:  Front Mol Neurosci       Date:  2017-09-07       Impact factor: 5.639

9.  Efficient Transduction and Expansion of Ovine Macrophages for Gene Therapy Implementations.

Authors:  Garyfalia Karponi; Spyridon Kritas; Evanthia Petridou; Eleni Papanikolaou
Journal:  Vet Sci       Date:  2018-06-18

10.  Real-Time Monitoring of Exosome Enveloped-AAV Spreading by Endomicroscopy Approach: A New Tool for Gene Delivery in the Brain.

Authors:  Nicola Salvatore Orefice; Benoît Souchet; Jérôme Braudeau; Sandro Alves; Françoise Piguet; Fanny Collaud; Giuseppe Ronzitti; Satoru Tada; Philippe Hantraye; Federico Mingozzi; Frédéric Ducongé; Nathalie Cartier
Journal:  Mol Ther Methods Clin Dev       Date:  2019-07-03       Impact factor: 6.698

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.